While Veracyte Inc has underperformed by -0.84%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, VCYT rose by 6.82%, with highs and lows ranging from $47.32 to $22.61, whereas the simple moving average jumped by 33.39% in the last 200 days.
On October 20, 2025, Canaccord Genuity started tracking Veracyte Inc (NASDAQ: VCYT) recommending Hold. A report published by Craig Hallum on March 20, 2025, Initiated its previous ‘Buy’ rating for VCYT. Goldman also Downgraded VCYT shares as ‘Neutral’, setting a target price of $37 on the company’s shares in a report dated December 05, 2024. Wolfe Research Initiated an Outperform rating on November 15, 2024, and assigned a price target of $50. UBS initiated its ‘Buy’ rating for VCYT, as published in its report on October 16, 2024. Guggenheim’s report from October 10, 2024 suggests a price prediction of $40 for VCYT shares, giving the stock a ‘Buy’ rating. Needham also rated the stock as ‘Buy’.
Analysis of Veracyte Inc (VCYT)
Further, the quarter-over-quarter increase in sales is 13.82%, showing a positive trend in the upcoming months.
In order to gain a clear picture of Veracyte Inc’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of 2.49% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 5.94, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 1.00M can be a very valuable indicator of volatility for VCYT stock. On a monthly basis, the volatility of the stock is set at 4.55%, whereas on a weekly basis, it is put at 5.15%, with a loss of -8.12% over the past seven days. Furthermore, long-term investors anticipate a median target price of $47.27, showing growth from the present price of $42.3, which can serve as yet another indication of whether VCYT is worth investing in or should be passed over.
How Do You Analyze Veracyte Inc Shares?
The USA based company Veracyte Inc (VCYT) is one of the biggest names in Diagnostics & Research. When comparing Veracyte Inc shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 111.40, there is a growth in quarterly earnings of 24.34%.
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 2.22%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 111.43% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
